Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Evangellos Felekouras"'
Autor:
Odysseas Chatzipanagiotou, Dimitrios Schizas, Michail Vailas, Marina Tsoli, Panagiotis Sakarellos, Maria Sotiropoulou, Alexandros Papalambros, Evangellos Felekouras
Publikováno v:
Journal of Neuroendocrinology. 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e0893eb3ac86b6b5d763df2cbb4715c
https://doi.org/10.1111/jne.13267
https://doi.org/10.1111/jne.13267
Autor:
null Odysseas Chatzipanagiotou, null Dimitrios Schizas, null Michail Vailas, null Marina Tsoli, null Panagiotis Sakarellos, null Maria Sotiropoulou, null Alexandros Papalambros, null Evangellos Felekouras
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e870421553e3fb6386f881e41d3befd
https://doi.org/10.1111/jne.13267/v3/response1
https://doi.org/10.1111/jne.13267/v3/response1
Autor:
Stavros Sifakis, Achilles Ploumidis, Aristidis Tsatsakis, Demetrios A. Spandidos, Ioannis Spyrou, Evangellos Felekouras, Vasilis P. Androutsopoulos, Alexandros Papalampros
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 35(10)
The cytochrome P450 CYP1A1 and CYP1B1 enzymes are phase I extrahepatic enzymes involved in the activation of pro-carcinogenic compounds to carcinogenic metabolites. Although differential overexpression of CYP1A1 and CYP1B1 has been documented at the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b227ad6402e1dd5710569da7c8fbc5
https://pubmed.ncbi.nlm.nih.gov/24957043
https://pubmed.ncbi.nlm.nih.gov/24957043
Autor:
Aristides, Polyzos, Evangellos, Felekouras, Theodore, Karatzas, John, Griniatsos, Dimitrios, Dimitroulis, Kostas, Polyzos, Kostas, Kontzoglou, Dimitrios, Mantas, John, Karavokyros, Nikolaos, Nikiteas, Nikolas, Tsavaris, Kostas, Syrigos, Irene, Vafiadis
Publikováno v:
Anticancer research. 32(9)
The combination of docetaxel, cisplatin and fluorouracil is considered to be one of the reference regimens for advanced gastric cancer, but due to its major myelotoxicity, its use in clinical practice has become limited. This prospective phase II stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0073b37bbee1ce25231e85fcd23acdbf
https://pubmed.ncbi.nlm.nih.gov/22993377
https://pubmed.ncbi.nlm.nih.gov/22993377